Q3 2023 Ambu A/S Earnings Call Transcript
/-
Good morning, everyone, and welcome to this Q3 2022-'23 financial results from Ambu. My name is Britt Meelby Jensen, I'm the CEO of the Company. And with me today, I have Thomas Frederik Schmidt, our CFO. So on the agenda today, I'll start going through the Q3 results with a business update, and then I'll hand over to Thomas to take us through the financials, and we will end the session today with a Q&A session.
Starting with the highlights from the Q3 this year, we have announced an 8% organic growth for the quarter, driven by a strong 23% growth in Endoscopy Solutions with Pulmonology returning to year-over-year growth and with a strong performance in Urology and ENT. We also report an EBIT margin for the quarter of 7.6%, having increased the full year outlook back in July to 5% to 6% from previous 3% to 5%.
Then I'm happy to announce a cash flow for the quarter of DKK 157 million. This drives us to an upgrade in terms of our expectations for the full year of improving the cash flow of over DKK 500 million for the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |